431P Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)
H.S. Rugo(University of California, San Francisco), A. Bardia(University of California, Los Angeles), S-A. Im(Seoul National University Hospital), S. Pernas Simon(Institut Català d'Oncologia), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), S. Wang(Sun Yat-sen University), Noelia Martínez-Jáñez(Instituto Ramón y Cajal de Investigación Sanitaria), Giuliano Santos Borges(Empresa de Pesquisa Agropecuária e Extensão Rural de Santa Catarina), David W. Cescon(Princess Margaret Cancer Centre), Masaya Hattori(Aichi Cancer Center), Yen‐Shen Lu(National Taiwan University Hospital), Junji Tsurutani(Showa University), S.M. Tolaney(Dana-Farber Cancer Institute), Darlington Mapiye(AstraZeneca (United Kingdom)), Kwame N. Atuah(AstraZeneca (United Kingdom)), Divij Verma(AstraZeneca (Spain)), Sabrina Khan(AstraZeneca (Netherlands)), B. Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Barbara Pistilli(Institut Gustave Roussy), K. Jhaveri(Memorial Sloan Kettering Cancer Center)
Cited by 0Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis